Brand/Development name: Abraxane
Company(ies): Abraxis BioScience
Principal Therapy Area: Cancer
£195 / $340 / €245
Abraxane (paclitaxel albumin-bound particles for injectable suspension) is an anticancer drug. Rapidly-growing tumours have been shown to take in and retain albumin, a natural protein in the body with a central role in transporting and distributing nutrients to cells. By wrapping a chemotherapeutic drug in albumin, tumour defences may be infiltrated, hijacking the albumin-activated gp60 pathway that may be used by tumours for nutrient support. Essentially, with this technology it is possible to deliver higher concentrations of active drug to the target site.
Abraxane has a safety profile marginally superior to other taxanes.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com